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Abstract:  
Objective: To analyse the impact of centralisation of radical cystectomy provision for 
bladder cancer in England, on post-operative mortality, length of stay, complications 
and re-intervention rate, from implementation of centralisation from 2002, until 2014. 
In 2002, UK policymakers introduced the Improving Outcomes Guidance (IOG) for 
urological cancers after a global cancer surgery commission identified substantial 
shortcomings in provision of care of radical cystectomies. One key recommendation was 
centralisation of cystectomies to high output centres. No study has yet robustly 
analysed the changes since IOG, to assess a national healthcare system which has 
mature data on such institutional transformation.  
 
Methods: Radical Cystectomies performed for bladder cancer in England between 
2003/2004 and 2013/2014 were analysed from Hospital Episode Statistics (HES) data. 
Outcomes including 30-day, 90-day, and one-year all-cause post-operative mortality, 
median length of stay, complications and re-interventions were calculated. 
Multivariable statistical analysis was undertaken to describe the relationship between 
each surgeon and the providers’ annual case volume and mortality.  
 
Results: 15,292 cystectomies were identified. Percentage of cystectomies performed in 
discordance with IOG reduced from 65.0% to 12.4%, corresponding with improvement 
in 30-day mortality from 2.7% to 1.5% (p=0.0235). Procedures adhering to IOG had 
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superior 30-day mortality (2.9% vs. 2.1%; p=0.0029) to those which did not, and 
superior one-year mortality (25.6% vs. 21.5%; p<0.001), length of stay (16 vs. 14days 
P<0.001) and re- intervention rates (33.6% vs. 30.0%; p<0.001). Each single extra 
surgery per centre reduced odds of death at 30 days by 1.5% (OR-0.985; 95%CI (0.977, 
0.992) and 1% at one year (OR-0.990; 95%CI (0.988-0.993)), and significantly reduced 
rates of re-intervention.  
 
Conclusion: Centralisation has been implemented across England since publication of 
the IOG in 2002. The improved outcomes shown, including that a single extra procedure 
per year per centre can significantly reduce mortality and re-intervention, may serve to 
offer healthcare planners an evidence base to propose new guidance for further 
optimisation of surgical provision, and hope for other healthcare systems that such 
widespread institutional change is achievable and positive. 
 
INTRODUCTION 
 
In 2015, a global commission on cancer surgery identified substantial shortcomings in 
provision of care, and was able to provide several key areas for improvement (1). 
Amongst these was the importance of surgical volume, processes and outcomes for 
delivering safe and effective cancer surgery. Super-centralisation of surgical services 
was proposed as one possible solution. 
 
 
There is an ongoing reconfiguration of cancer surgery services in the United Kingdom, 
in response to the NHS Cancer Plan and Improving Outcomes Guidance (IOG) released 
over a decade ago (2). One of the key recommendations of these guidelines was the 
centralisation of radical cystectomies (RCs) for bladder cancer to high-output 
centres. The IOG recommended that radical surgery for prostate and bladder cancer 
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should be provided by teams serving populations of one million or more, and carrying 
out a cumulative total of at least 50 operations per annum. Surgeons carrying out 
small numbers of either operation (a total of five or fewer per annum) were advised 
to refer this work on to more specialised colleagues. The overall aim was to reduce 
30-day mortality rate to 3.5% or less for all providers and surgeons performing RCs 
across the UK. Since these guidelines were published there has been a shift in the 
national distribution of RCs to high output centres (3). 
 
The volume-outcome relationship for RCs has been previously described, indicating a 
consistent inverse association between increased surgical workload and outcomes 
including mortality and post-operative complications (4,5). The main  body  of  
evidence  supports  the  centralisation  process  for  RCs  (6-11). 
However, due to the complexity of this debate, doubts remain about a direct link 
between centralisation and improved outcomes.  Furthermore, the methodological 
cogency of some of the published literature has also come under scrutiny (11-13). 
 
The location and number of cystectomies performed in the NHS in England are all 
recorded in the Hospital Episode Statistics (HES) database, allowing the centralisation 
process to be tracked. HES also records patient demographics and other variables 
including post-operative complications. We reviewed the post- operative outcomes 
for RCs performed in England over the 11-year period following the introduction of 
IOG for urological cancers, to ascertain the nature and describe the impact of 
reconfiguration of RC provision.  
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 MATERIALS AND METHODS 
 
Database inclusions and variable coding 
 
All adult patients aged 18 and over, resident in England undergoing a cystectomy with 
a diagnosis of bladder cancer with admission dates between 1st April 2003 and 31st 
March 2014 were included into the analysis.  Cystectomies were identified using the 
Office of Population Censuses and Surveys Classification of Interventions and 
Procedures (OPCS-4) codes M34*, and prostatectomies were ascertained using code 
M61*.    Bladder cancer was identified using the International Statistical 
Classification of Diseases and Related Health Problems tenth revision (ICD-10) code 
C67*.  We excluded all procedures where the total length of stay for the RC patient 
was two days or less and where there was no record of the patient dying in hospital. 
 
The number of prostatectomies and cystectomies performed in each centre each year 
was also extracted. Procedures were identified as IOG guidance compliant if the 
centre where the surgery took place had conducted 50 or more prostatectomies and 
cystectomies; and if the operating surgeon had performed more than 5 of either type 
of surgery in that year. 
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Patient demographic variables 
Patient’s age; gender; ethnicity; indices of multiple deprivation (IMD) 2007 score and 
Charlson co-morbidity score were extracted for each procedure.  The Charlson score 
predicts  one-year mortality for a patient who may have a range of  co -
morbidities,  and is considered in three categories: 0, 1–4, and ≥5. The IMD are an 
overall score of deprivation derived from seven domains; income, employment,  health,  
education,  training  and  skills,  barriers  to  housing  and services, crime and living 
environment. Scores were used in models as a continuous variable, but quintiles 
derived from these scores; classified from 1 (most deprived) to   5 (least   deprived) 
were   also   used   for   categorical comparisons. 
 
 
Outcome variables 
 
We ascertained 30-, 90-day, and one-year all-cause post-operative mortality. Deaths 
within 1 year are ascertained through linkage between HES records and the 
Office of National Statistics mortality data based on death certificates. Length of stay 
is the time (in days) spent in hospital during the primary admission for RC. Median 
length of stay (with interquartile range) is referred to in unadjusted analyses. 
Complications and re-interventions were calculated using the coding set out in 
Mayer et al (15). 
 
 
Data exclusions 
 
Records in the HES database are for ‘hospital episodes’ which relate to a period of 
care for a patient under a single specialist. A stay in hospital can be made up of one or 
more episodes of care. For each RC, if no date of discharge was available on the 
episode, but was included in another episode within the same stay then that date of 
discharge was used. Records with no updateable discharge date were excluded, as it 
was not possible to calculate length of stay. If there was a date of death which 
occurred more than one day before the procedure, then the record was removed as it 
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is not possible to tell whether an error in data linkage has occurred. For those where 
the date of death occurred the day before the procedure and the HES record stated 
that the patient died during the stay then the length of time between operation and 
death was updated to zero days. Patients with no recorded age or sex were also 
removed from analyses as these two variables are always used in determining the 
patient ID along with NHS number. Patients whose region of residence was recorded 
as being outside of England, or where this information was not available were also 
removed from analysis as follow-up may have occurred elsewhere. 
 
 
  Univariable and multivariable analysis 
Categorical variables were tested for association with the 30-day and one-year 
outcome   variables   using   the χ2 test.   Kaplan   Meier   survival   curves   were 
produced to examine survival over time.  Multivariable mixed effects logistic 
regression was used to investigate 30-day death rates; complication rates; re-
intervention rates and deaths within one year of the operation, adjusting for 
factors which may have an impact on outcome. To account for uncaptured differences 
at each hospital, a centre-level random effect was added when considering the effects 
of number of procedures per centre. Survival was modelled using Cox regression. For 
all regression models, continuous variables were fitted using suitable transformations, 
such as a log transformation of IMD and Charlson score, and a cubic spline for age. 
The multivariable models were first fitted with all variables; and then tested to see 
whether any variables could be excluded from the analyses. 
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Statistical analyses were carried out using R statistical package (version 3.0). A P- 
value of <0.05 was considered statistically significant in the analysis. 
 
RESULTS 
 
Centralisation 
 
The study included 15,292 radical cystectomies; 11,793 (71.1%) in male patients, and 
3,499 (22.9%) in females, with a median age of 69 years (IQR 62, 74). The majority 
of patients did not have a co-morbidity recorded (53.8%) and 16.0% came from the 
most deprived regions, according to IMD deprivation scores. 
 
 
During the study period there was a clear trend toward centralisation of provision of 
RCs: the number of operations performed increased annually, and the number of 
urological surgeons and providers performing RCs reduced annually (Figure 1).  The 
percentage of radical cystectomies performed by a provider in discordance with IOG 
guidelines reduced each year, from 52.7% in 2003 to 2.0% in 2013 (Figure 2). The 
percentage of radical cystectomies performed by a surgeon in discordance with IOG 
guidelines also reduced each year, from 29.9% in 2003 to 11.1% in 2013 (Figure 2). 
By 2013 the percentage of cystectomies being performed in discordance with IOG 
guidelines on provider or surgeon volume was 12.4%, a reduction from 60.7% in 2003 
(Figure 2). Over the 11-year period there was a significant improvement in the overall 
30-day crude mortality rate with a reduction from 2.7% to 1.5% (p=0.024), and 90-day 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
crude mortality dropped from 7% to 4%. The number of providers performing at least 
fifty surgeries increased from 35(26.7%) in 2003 to 53(91.4%) in 2014.  
 
 
During   the   study   period,   there   were   4,547   cystectomies   performed   in 
discordance with the guidelines, compared to 10,745 in concordance (Table 1). 
 
There were significant differences in characteristics between the two patient groups, 
with the compliant group having slightly older patients (compliant: median 69 
years, IQR 62-74, non-compliant: median 68 years, IQR 61-74), and the proportion of 
patients over 70 y e a r s  w a s  4 7 . 2 %, c o m p a r e d  w i t h  4 3 . 4 % i n  t h e  n o n -
compliant g r o u p  (p<0.001). The patients treated in the compliant group also had 
more co- morbidities (35.6% Charlson score 5+) compared to the non-compliant group 
(32.5% Charlson score 5+; p<0.001). The outcomes for those cystectomies performed 
in concordance and discordance with IOG guidelines were directly compared (Table 1, 
Figure 3). The compliant group demonstrated significantly better 30-day mortality 
rates (2.1% vs. 2.9%; p=0.003), 90-day mortality rates (5.2% vs. 7.2%; p<0.001) one-
year mortality rates (21.5% vs. 25.6%; p<0.001), length of stay (14 vs. 16 days; 
P<0.001) and re-intervention rates (30.0% vs. 33.6%; p<0.001) compared to the non-
compliant group (Figure 3). 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
After adjusting for age, co-morbidities, gender, deprivation, readmissions and re- 
interventions, people were more likely to die at 30-days (OR 1.41 (95% CI:1.13-
1.76)), and at 1 year (OR 1.31 (95% CI (1.21, 1.43)) if they were in the non- compliant 
group compared to the compliant group. This pattern is continued if the IOG 
compliance variable was removed and just the adjusted number of procedures  per 
centre  is modelled,  with each extra  RC reducing the odds of death at 30- days by 
1.5%(OR 0.985; 95% CI (0.977, 0.992) and 1% at one year (OR 0.990; 95% CI(0.988-
0.993)). 
 
 
After adjustment for confounders, there were no statistically significant differences in 
complication rates (OR 0.96, (95% CI 0.88, 1.04); but there was a difference in re-
intervention rates, with the non-compliant group more likely to have a re-intervention 
(OR 1.20 (95% CI: 1.12-1.30)). Here, examining just the number of operations per 
centre, instead of looking at IOG compliance, showed that each additional procedure 
also had no significant effect on the complications rate, but significantly decreased the 
odds of re-intervention (OR 0.99, (95% CI 0.991 – 0.995)). 
 
The compliant group also had an increased median survival time over the non- 
compliant group: 5.41 years (95% CI: 5.05-5.85) vs. 4.07 (95% CI: 3.69-4.50) (Figure   
3). When censoring the data at 90 days, the non-compliant group have a median 
survival of 5.1 years, whereas those in the compliant survive 6.4 years (p<0.001). 
Adjusting   for   age, co-morbidities, gender   and   deprivation, discordance with IOG 
increased the hazard of death (HR 1.17; 95% CI: 1.12- 1.23).  Furthermore, the   
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incremental   effect   of   increasing   the   number   of procedures conducted by a 
provider by one significantly reduced the hazard of death (HR=0.993; 95% CI=0.992-
0.995) 
 
DISCUSSION 
 
To our knowledge, this is the largest UK study to date robustly assessing the process of 
centralisation of RC provision. A recent study by Hounsome et al has investigated 
outcomes after radical cystectomy since the introduction of IOG until 2010, but their 
analyses only provided circumstantial evidence as the comparison of outcomes 
between IOG compliant and non-compliant centres was not made (33). When analysing 
survival outcomes, they compare outcomes with nationally representative background 
rates making no comment on the impact on the effects of centralisation, and 
importantly, adjustment for important potential confounders, such as the changing age 
of the population during this time, amongst others, was not made. Our analyses are 
directly comparing the outcomes of patients undergoing operations from IOG 
compliant and non-compliant centres, with multivariable adjustment for several 
known confounders. 
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Due to the complexity of IOG guidance, flexibility was originally given around 
implementation timescales, but it soon became apparent that local health economies 
had deferred action in favour of other priorities. This was addressed by employment of 
agreed milestones for health authorities after 2006, and our results demonstrate a 
clear and profound acceleration in centralisation of RCs provision after this date, which 
reaches a plateau after 2011 (Figure 2). This finding corroborates the Lancet Oncology 
Commission’s suggestion of the importance of politics and policy in this area. 
 
 
There has been a clear trend in centralisation since publication of IOG guidelines in 
2 0 0 2 .  The  number  of  cystectomies  has  risen  each  year  but  number  of 
providers and surgeons have dropped (Figure 1). In 2003/4 there were 290 surgeons 
and 135 providers, reducing to 199 surgeons and 60 providers by 2013-14 (Figure 
1). Cystectomies in concordance with IOG since its publication have an improved 30-
day and one-year mortality rate over those in discordance. Furthermore, median 
overall survival rates were significantly improved for guidance compliant procedures 
(5.41 years) over guidance non-compliant procedures (4.07 years). 
 
 
The difference seen in survival outcomes in our study between compliant and non-
compliant procedures is more marked than those described in previous studies in the 
UK (14-16). This disparity may well be as a result of the acceleration in 
centralisation noted after 2007.  The last national study in England looking at 
outcomes of radical cystectomies with specific analysis of the impact of centralisation 
only analysed information up to 2007, just five years after IOG had been 
introduced, when 56.1% of cystectomies were still in discordance with IOG guidelines 
(Figure 2). By 2011-12, only 12.5% of cystectomies were in discordance with IOG 
guidance (Figure 2). 
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This study strengthens the link between high volume providers and improved 
outcomes, by including all surgeons and centres therefore analysing “real data”, but has 
not addressed how this is occurring. An exact cause-effect relationship is unlikely to be 
formulated, but the relationship is most probably multifactorial (17,18). There are 
numerous potential reasons for the superior outcomes seen. Firstly, high patient 
volumes have inherent benefits ranging from increased surgeon experience to 
improved numbers for audits, trials and research. A good example is robotic surgery 
which requires high numbers of patients per year to be cost-effective (19). High 
volume providers also often have additional services at their disposal which may 
improve perioperative selection of patients, allow for adoption of enhanced recovery 
pathways, provide additional treatments, improve treatment of post-operative 
complications and improve follow up and surveillance of patients (17). Furthermore, 
local access to specialist oncology and radiotherapy services at high volume centres 
may impact overall survival. Finally, having fewer hospitals performing a certain type 
of highly complicated intervention allows better regulation and provision of more 
uniform and consistent care. 
 
 
 
There are an increasing number of radical cystectomies being performed each year 
even though the number of newly diagnosed bladder cancers is decreasing (20). As 
outcomes have improved more patients who are over 70 years or have serious co-
morbidities are being considered suitable for surgery (21). The majority of this 
group of patients are being operated on at high volume providers by high volume 
surgeons (Table 1). Our finding that over the 11- year period crude 30- day 
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mortality has dropped from 2.7% to 1.5% is encouraging, but remains sub- optimal 
given previously described single-centre experiences of significantly better outcomes 
both in the UK and United States (22-24). However, a clear correlation between the 
process of centralisation in the last decade and improved survival post-cystectomy is 
shown in this paper. Indeed, when the adjusted number of procedures per centre was 
modelled, with each single extra surgery the odds of death significantly reduced at 
30 days and at one year, as did re-intervention rates. This is a novel observation that 
has not yet been previously published. 
 
Several papers have been critical of using the HES database due in part to coding errors 
(25). Potential sampling bias exists and there is the possibility that a very small number 
of patients with RCs were not captured. Furthermore, there will undeniably be an 
impact on our findings from hospital mergers and closures, although these would 
account for a very small proportion of our dataset. Nevertheless, a core limitation of this 
study is that it is a secondary analysis of administrative data, therefore misclassification 
bias may exist due to coding errors. We were not able to fully capture the outcomes of 
outpatient visits and records of potentially minor events. Our minor complication rates 
were therefore lower than that reported by single-institution series (26,27). Detailed 
oncological information, such as chemotherapy, stage and grade of MIBC was also not 
fully captured in this review.. England, unlike North America or other European 
countries is geographically very tight within a single health care service (NHSe). We 
recognise this as an assumption and therefore a potential limitation to the study.(28) 
However, the Cancer registry (ONS) suggests that region wide stage-specific variations 
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are uniform across England. Hence, we can presume that the disease characteristics 
between IOG compliant and non-compliant centres are also uniform.  
Moreover, the retrospective nature of this analysis means that potential unmeasured 
confounders that can account for differences in outcomes such as smoking status (28), 
albumin levels (29,30), and outpatient management strategies will not be captured. 
Surgeon skill and experience is another potential uncaptured confounder, as the 
British Association of Urological Surgeons (BAUS) annual workforce reports at the 
beginning and end of the study period show the composition of the surgical workforce 
changed greatly. 
 
 
In our methodology we have taken steps to minimise the impact of potential coding 
errors, and although coding errors are likely to have a bearing on our results we 
feel this will be negligible. The key search criteria of bladder cancer and cystectomy 
along with outcomes such as mortality and length of stay leave little space for 
interpretation. Furthermore, it is noteworthy that our analysis is of a population-
based dataset and no statistical assumptions or weighting was necessary to achieve 
patient numbers, unlike some previous studies (31). Given the association between 
centralisation and improved outcomes in RCs over the last decade described in 
this paper, it would be logical to consider that continuation of the centralisation 
process could further enhance outcomes. This raises the question of the optimum 
number of centres and surgeons needed to achieve the most favourable outcomes 
and, whether a decade on from IOG, new guidance needs to be provided to optimise 
service reconfiguration. 
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Since the first volume-outcome relationships in medical care were reported by Luft et 
al in 1979 (32), there has been a persistent and sometimes emotional debate about 
whether certain sorts of complex, elective care should be restricted to high-volume 
medical centres. A decade ago IOG guidance set out to centralise surgical care for 
cancer as one method for improving cancer outcomes in the UK, yet a robust and up to 
date review of this process is lacking in the literature. Our group’s analysis of 
cystectomies provides this information for just one cancer type, but goes some way to 
showing the impact of centralisation. We have demonstrated that the variance in 
outcomes between high and low volume surgeons and providers is more profound 
than that shown by any previous UK studies. We have also demonstrated a sudden and 
steep acceleration of the process of centralisation after 2007, indicative of the NHS 
Cancer Reform Strategy which sought to push for concordance with IOG; no studies 
have extensively analysed outcomes after this date. The effects of caseload levels for 
surgeons and providers proposed in this paper, including the fact that a single extra 
procedure per year per centre can significantly reduce mortality and re- intervention, 
may serve to offer healthcare planners an evidence base to propose new guidance for 
further optimisation of RC provision.  
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Table 1: Comparison of characteristics between cystectomies which are 
compliant and those which are non-compliant with IOG guidance (all years: 
2003/04 - 2013/14).  
 
Characteristic Not complying Complying Significance 
Total number of cystectomies 4547 10745 - 
Patient age (median, IQR) 68 (61 - 74) 69 (62 - 74) P<0.001 
Patient age >70 (n, %) 1,972 (43.4%) 5,075 (47.2%) P<0.001 
Patient gender: Male (n, %) 3,433 (75.5%) 8,360 (77.8%) p = 0.002 
Patient IMD 
quintile 
(n, %) 
1 (most 
deprived) 
796 (17.5%) 1,649 (15.3%) 
P<0.001 
2 910 (20.0%) 1,928 (17.9%) 
3 984 (19.7%) 2,353 (21.9%) 
4 967 (21.3%) 2,398 (22.3%) 
5 (least 
deprived) 
796 (17.5%) 1,649 (15.3%) 
Patient 
Charlson co-
morbidity score 
0 2,626 (57.8%) 5,603 (52.1%) 
P<0.001 1-4 441 (9.7%) 1,319 (12.3%) 
5+ 1,480 (32.5%) 3,823 (35.6%) 
30 day mortality (n, %) 133 (2.9%) 227 (2.1%) 0.003 
90 day mortality (n,%) 329 (7.2%) 564 (5.2%) P<0.001 
1 year mortality (n, %) 1,165 (25.6%) 2,306 (21.5%) P<0.001 
Length of stay (median, IQR) 16 (13, 23) 14 (11, 19) P<0.001 
Re-intervention required  1,526 (33.6%) 3,222 (30.0%) P<0.001 
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(n, %) 
Median survival (years) 4.1 5.4 P<0.001 
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Table 2 Results of multivariable mixed effects logistic regression. 
 
  Mortality 30 days Mortality 90 days Mortality 1 year Complications Re-intervention 
  OR(95% CI) P-Value OR(95% CI) P-Value OR(95% CI) P-Value OR(95% CI) P-Value OR(95% CI) P-Value 
Male (reference 
Group) 1   1   1   1   1   
Female 
1.02 (0.79, 
1.32) 0.8679 
1.21 (1.03, 
1.42) 0.0201 
1.40 (1.28, 
1.53) <0.0001 
0.98 (0.89, 
1.06) 0.5679 
1.05 (0.97, 
1.14) 0.2210 
log (IMD Score +1) 
1.18 (1.01, 
1.37) 0.0321 
1.20 (1.09, 
1.33) 0.0002 
1.12 (1.06, 
1.18) <0.0001 
1.07 (1.02, 
1.12) 0.0111 
1.00 (0.95, 
1.05) 0.9340 
log(Charlson + 2) 
1.50 (1.34, 
1.69) <0.0001 
1.48 (1.37, 
1.59) <0.0001 
1.38 (1.32, 
1.44) <0.0001 
1.42 (1.37, 
1.48) <0.0001 
1.30 (1.25, 
1.35) <0.0001 
Non-Compliant 
1.41 (1.13, 
1.76) 0.0022 
1.46 (1.26, 
1.69) <0.0001 
1.31 (1.21, 
1.43) <0.0001 
1.00 (0.92, 
1.08) 0.9946 
1.20 (1.12, 
1.30) <0.0001 
Readmitted 
0.17 (0.10, 
0.29) <0.0001 
1.59 (1.35, 
1.86) <0.0001 
1.31 (1.19, 
1.45) <0.0001         
Reintervened 
2.67 (2.15, 
3.30) <0.0001 
2.29 (2.00, 
2.63) <0.0001 
1.42 (1.31, 
1.54) <0.0001         
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Figure 1: Number of providers, urologists and urologists performing cystectomies in 
England from 2003 until 2014. Clearly the crude number of urologists increases over 
time, whereas the number of those urologists performing cystectomies reduces, as do 
the number of centres performing cystectomies. 
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Figure   2:   A   comparison   of   the   numbers   of   cystectomies   performed   in 
discordance with IOG guidelines in England from 2003 until 2014, and the number of 
cystectomies overall during this time. A clear trend can be seen for reducing number 
of discordant surgeons and centres, yet increasing numbers of cystectomies overall. 
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Figure 3: Kaplan Meier Survival graphs, comparing overall survival between IOG 
compliant and non-compliant centres.  There is a better overall survival seen with 
patients treated at IOG compliant centres, as the Kaplan Meier curves separate early 
and stay separated. 
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